

TENDER NO. BMSIC/DRUGS/24-03

Check list - I: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name :- Daffodills Pharmaceuticals Ltd.

Total Number of Pages Submitted in bid documents:- 1-116

Sl. No	SBD clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD as mentioned in the Check List	Document/ fees submission status (Yes/ No)	Page number	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3. (a)	Tender Fee (Non-Refundable) of Rs 10,000/- + GST @18%, Total Rs 11,800 shall be submitted online (On E-Proc-2). This fee is payable only once for one tender irrespective of items contained therein.	Yes	114	Yes	—
2	3.(b)	EMD shall be submitted ONLY in form of Bank Guarantee (Offline mode), drawn in favor of Managing Director, Bihar Medical Services and Infrastructure Corporation Limited from any Scheduled/Nationalized bank payable at Patna, as mentioned in Clause 2, as per following table:- S.N. No. of drugs quoted EMD Amount 1 Upto 5 drugs Rs1,00,000/- (One Lakh only) 2 For 6 to 10 Drugs Rs 2,00,000/- (Two Lakh only) 3 For 11 to 15 Drugs Rs 3,00,000/- (Three Lakh only) 4 For 16 to 20 Drugs Rs 4,00,000/- (Four Lakh only) 5 More than 20 Drugs Rs 5,00,000/- (Five Lakh only)	Yes	15-19	Yes	As per Bid document clause 3(b) BG Submitted for EMD must be Schedule/Nationalized Bank Payable at Patna But firm has not submitted the same.
3	3.(c)	Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.	Yes	68-108	Yes	—
4	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V .	Yes	42	Yes	—
5	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	05-06	Yes	—
6	3.(l)	Copies of the Audited Balance Sheet and Profit and Loss statement showing details of their annual average turnover not less than 25 Crores (Twenty-Five) for any three of the last four consecutive financial years (Auditor/CA certificate of turnover will not be accepted). Self-attested copies are to be submitted.	Yes	53-65	No	Copies of the Audited Balance Sheet and Profit and Loss statement Submitted only for two years i.e for F.Y-2022-2023 & F.Y-2021-2022
7	3.(m)	Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).	Yes	12-14	Yes	—
8	3.(p)	Copy of PAN Card of the bidder company should be submitted (self-attested).	Yes	20	Yes	—
9	3.(q)	Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).	Yes	23	Yes	—

Anil Kumar
29/7/24


Kul


TENDER NO. BMSIC/DRUGS/24-03


Check list - II: Evaluation sheet to be used for preliminary evaluation of technical bids


Company Name:- M/s Daffodills Pharmaceuticals Ltd. Total Number of Pages Submitted in bid documents:- 116

Sl. No	SBD Clause serial No	Description of the Clause/ Technical Eligibility Criteria as per SBD, as mentioned in Check List	Document/ fees submission status (Yes/ No)	Page Number as numbered by BMSICL	Do the provided documents meet the eligibility criteria ? (Yes/ No)	Remarks
1	3.(d)	The details of Bidder Name, Address, Telephone Number, Fax. Number, e-mail address of the bidder and of the Managing Director / Partners / Proprietor should be submitted in Annexure-V.	Yes	42	Yes	
2	3.(e)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm to sign the documents should be submitted.	Yes	5-6	Yes	
3	3.(f)	Minimum three years old valid Manufacturing License of the quoted product.	Yes	31-39	No	For quoted product NIT sl. No. 12, 17, 19, 30 & 44 product approval is less than 3 years in submitted documents i.e. product approval date is 29.04.2022
4		Manufacturing License along with approved product list must be valid till the last date of the submission of tender.	Yes	31-39	No	
5		Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of 'New Drug' as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable. Explanation- In case of Importers Permission in Form 45 from DCGI is required as Per Drugs & Cosmetics Act 1940 & Rules 1945.	Yes	24-30	No	For quoted product NIT sl. No. 17 of MSC last year 2023-24 not submitted.
6		For all regulated products, the bidder should have at least two years of manufacturing and marketing experience of the particular items as a manufacturer for each regulated product quoted in the tender. However, this would not apply to regulated products which have been licensed by DCGI less than two years ago. A certificate from DCG (I) shall be required for all new regulated products to this effect.	NA	NA	NA	


19/7/2024


19/7/2024


19/07/2024


19/07/24

7		FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.	NA	NA	NA	
8		Valid Pollution Control Clearance Certificate in accordance with Water [Prevention and control of Pollution] Act, 1974 & Air [Prevention and control of Pollution] Act, 1981 and Hazardous Wastes (Management, Handling & Trans Boundary Movement) Rules 2008 (Self Attested Copy of Certificate to be enclosed) (as applicable).	Yes	42-47	Yes	
9		Bidders shall submit self-attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.	Yes	31-39	No	For quoted product NIT sl. No. 12, 17, 19, 30 & 44 product approval is less than 3 years in submitted documents i.e. product approval date is 29.04.2022
10	3.(g)	In case of Importer, the bidder (importer) firm must have minimum three yearsold valid import License of the quoted product. All Quoted products should be accompanied by their invoices, statement and import License showing that the quoted product is being imported and sold in India by the bidder (Importer) firm minimum for Last three years. Import license must be valid on the last date of submission of tender.	NA	NA	NA	
11	3.(h)	Bidder must have Market Standing Certificate (in India) of minimum three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.	Yes	24-30	No	For quoted product NIT sl. No. 17 of MSC last year 2023-24 not submitted.
12	3.(i)	Non-Conviction Certificate (NCC) issued by the concerned Licensing Authority from Drugs Control Administration of the state for last three years should be submitted (wherever applicable). It should be not more than one year old. Self-attested copies are to be submitted.	Yes	3	Yes	
13	3.(j)	WHO-GMP/GMP (Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/Drugs Control Department, (wherever applicable). The GMP certificate must not be older than one year from the date of publication of tender. Self-attested copies are to be submitted. Explanation- Generally the GMP Certificate is issued for one-year validity. Hence the provision that it should not be older than one year from the date of publication of tender implies mutatis mutandisthat the GMP certificate should remain valid till the date of submission of tender.	Yes	8-10	Yes	
14	3.(k)	Maximum Production Capacity Certificate (Section wise) issued by concerned Licensing Authority from Drugs Control Department highlighting the quoted product section (wherever applicable). Self-attested copies are to be submitted. In case of Importer, an affidavit (with Stamp) sworn before first class magistrate/ Notary stating the batch production capacity of the firm and also that said production (Importing) capacity shall be adequate for requirement laid in NIT. Importer will have also to submit Invoices/evidence of import in items of said product with quantity details.	Yes	11	Yes	

[Signature]
19/07/24

[Signature]
19/07/2024

[Signature]
19/07/2024

[Signature]
19/07/24

15	3.(n)	The tenderer should give an affidavit (with stamp) sworn before first class magistrate / Notary stating that the firm & its quoted product is not black listed /Debarred currently (as on the date of submission of the tender) by Central Government / Central Government agencies/any state government or any of the state government agencies / or any Drug procurement agencies or by BMSICL as per Annexure-II .	Yes	4	Yes	
16	3. (o)	List of items quoted in prescribed format as per Annexure-III duly signed.	Yes	2	Yes	
17	5.(k)	An Affidavit (with stamp) regarding acceptance of tender conditions to be submitted by the bidding firm as per Annexure-IV .	Yes	21-22	Yes	
18	5.(l)	Filled check list as per given Annexure-VI to be submitted at the time of uploading the bid.	Yes	40-41	Yes	
19	7.(c)	Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.	Yes	5-6	Yes	
20	10.(c)	If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.	NA	NA	NA	
21	2(d) Explanation	The price quoted by the bidders must not exceed the ceiling price as fixed by NPPA (National Pharmaceutical Pricing Authority) as per the provision of "Drugs Price Control Order" (wherever applicable) and the quoted rate should be at least 20% less than its MRP. In extraordinary cases the Managing Director, BMSICL has discretion to take decision. Explanation- In order to ensure procurement of the tendered drugs at the most appropriate and competitive rate, the bidders are directed to quote their lowest price as compared to the Rate provided to their respective Distributors/ Dealers/Wholesalers/ Carrying and Forwarding Agents/Authorized depot sales point in the State of Bihar. A Notarized affidavit to this effect on a Rs 100/- Non-judicial Stamp Paper should be submitted with the Bid in the prescribed format as mentioned in Annexure-VIII .	Yes	50	Yes	

[Signature]
19/7/24

[Signature]
19/7/2024

[Signature]
19/07/2024

[Signature]
19/07/24




TENDER NO. BMSIC/DRUGS/24-03

Check list - III: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Daffodills Pharmaceuticals Ltd. Total Number of Pages Submitted in bid documents:- 116

Sheet to be used for verification of product approval and market standing

Sl. No	NIT Sl. No	Name of the Quoted Drug		Pharmacopoeial Specification/ Strength		Pack Size		Dosage Form		Approval Details			Last 3yrs market standing certificate/ New Drug
		As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	As per NIT	As per Approval	Approval From	Approved Upto	Approved in Brand /Generic Name	
1	12	Ceftriaxone	Ceftriaxone Injection IP	1g	Each vial contains: Ceftriaxone Sodium IP Eq. to Ceftriaxone 1000 mg	Vial	Vial	Powder for Injection	Injection	29.04.2022	31.12.2026	Generic	Submitted (page no. 27)
2	17	Dopamine HCl	Dopamine Injection IP	40 mg/ml	Each 5 ml contains: Dopamine Hydrochloride IP 200 mg	5 ml Ampoule	Not mentioned	Injection	Injection	29.04.2022	31.12.2026	Generic	Submitted but current year MSC not submitted
3	19	Etophylline + Theophylline	Etophylline & Theophylline Injection IP	169.4mg + 50.6mg per 2ml	Each 2 ml contains: Etophylline IP 169.4 mg Theophylline IP 50.6 mg	2 ml Ampoule	Not mentioned	Injection	Injection	29.04.2022	31.12.2026	Generic	Submitted (page no. 26)
4	30	Meropenem	Meropenem Injection IP	1g	Each vial contains: Meropenem Trihydrate IP Eq. to Anhydrous Meropenem 1000g	Vial	Vial	Powder for Injection	Injection	29.04.2022	31.12.2026	Generic	Submitted (page no. 28)
5	44	Tranexamic acid	Tranexamic acid Injection IP	100mg/ml	Each ml contains: Tranexamic Acid IP 100 mg	5ml Ampoule	Not mentioned	Injection	Injection	29.04.2022	31.12.2026	Generic	Submitted (page no. 26)

 19/11/24
 19/11/2024
 19/07/2024
 19/07/24

TENDER NO. BMSIC/DRUGS/24-03

Check list - IV: Evaluation sheet to be used for preliminary evaluation of technical bids

Company Name:- M/s Daffodills Pharmaceuticals Ltd. Total Number of Pages Submitted in bid documents:- 116

Sheet for verification of licence details

Sl. No.	NIT Sl. No	Name of the Drug as per NIT	Manufacturer		Importer		Validity		GMP/ WHO GMP/ COPP (Import)	
			Forms Number	Manufacturing license Number	Forms Number	Import license Number	From	To	From	To
1	12	Ceftriaxone	28	8/SC/P/1996	NA	NA	15.05.1996	31.12.2026	25.08.2022	02.12.2024
2	17	Dopamine HCl	28	8/SC/P/1996	NA	NA	15.05.1996	31.12.2026	25.08.2022	02.12.2024
3	19	Etophylline + Theophylline	28	8/SC/P/1996	NA	NA	15.05.1996	31.12.2026	25.08.2022	02.12.2024
4	30	Meropenem	28	8/SC/P/1996	NA	NA	15.05.1996	31.12.2026	25.08.2022	02.12.2024
5	44	Tranexamic acid	28	8/SC/P/1996	NA	NA	15.05.1996	31.12.2026	25.08.2022	02.12.2024

Note:- Assisted in technical evaluation in reference to letter no. BMSIC/40030/214-2024/3159 dt 10.07.2024 on the basis of documents provided by BMSICL as check list II, III & IV. Provided checklist compiled with due diligence and care. In spite, some inadvertent discrepancies could have been crept in. Humble request to all concerned to bring to the notice in due time if any discrepancies are observed for rectification.

[Signature]
19/7/24

[Signature]
19/7/2024

[Signature]
19/07/2024

[Signature]
19/07/24